Uncovering the unique characteristics of different groups of 5-HT5AR ligands with reference to their interaction with the target protein.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacological Reports Pub Date : 2024-10-01 Epub Date: 2024-07-06 DOI:10.1007/s43440-024-00622-4
Szymon K Kordylewski, Ryszard Bugno, Andrzej J Bojarski, Sabina Podlewska
{"title":"Uncovering the unique characteristics of different groups of 5-HT<sub>5A</sub>R ligands with reference to their interaction with the target protein.","authors":"Szymon K Kordylewski, Ryszard Bugno, Andrzej J Bojarski, Sabina Podlewska","doi":"10.1007/s43440-024-00622-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The serotonin 5-HT<sub>5A</sub> receptor has attracted much more research attention, due to the therapeutic potential of its ligands being increasingly recognized, and the possibilities that lie ahead of these findings. There is a growing body of evidence indicating that these ligands have procognitive, pro-social, and anti-depressant properties, which offers new avenues for the development of treatments that could address socially important conditions related to the malfunctioning of the central nervous system. The aim of our study was to unravel the molecular determinants for 5-HT<sub>5A</sub>R ligands that govern their activity towards the receptor.</p><p><strong>Methods: </strong>In response to the need for identification of molecular determinants for 5-HT<sub>5A</sub>R activity, we prepared a comprehensive collection of 5-HT<sub>5A</sub>R ligands, carefully gathering literature and patent data. Leveraging molecular modeling techniques, such as pharmacophore hypothesis development, docking, and molecular dynamics simulations enables to gain valuable insights into the specific interactions of 5-HT<sub>5A</sub>R ligand groups with the receptor.</p><p><strong>Results: </strong>The obtained comprehensive set of 2160 compounds was divided into dozens of subsets, and a pharmacophore model was developed for each group. The results from the docking and molecular dynamics simulations have enabled the identification of crucial ligand-protein interactions that are essential for the compound's activity towards 5-HT<sub>5A</sub>R.</p><p><strong>Conclusions: </strong>The findings from the molecular modeling study provide valuable insights that can guide medicinal chemists in the development of new 5-HT<sub>5A</sub>R ligands. Considering the pharmacological significance of these compounds, they have the potential to become impactful treatments for individuals and communities in the future. Understanding how different crystal/cryo-EM structures of 5-HT<sub>5A</sub>R affect molecular modeling experiments could have major implications for future computational studies on this receptor.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11387456/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43440-024-00622-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The serotonin 5-HT5A receptor has attracted much more research attention, due to the therapeutic potential of its ligands being increasingly recognized, and the possibilities that lie ahead of these findings. There is a growing body of evidence indicating that these ligands have procognitive, pro-social, and anti-depressant properties, which offers new avenues for the development of treatments that could address socially important conditions related to the malfunctioning of the central nervous system. The aim of our study was to unravel the molecular determinants for 5-HT5AR ligands that govern their activity towards the receptor.

Methods: In response to the need for identification of molecular determinants for 5-HT5AR activity, we prepared a comprehensive collection of 5-HT5AR ligands, carefully gathering literature and patent data. Leveraging molecular modeling techniques, such as pharmacophore hypothesis development, docking, and molecular dynamics simulations enables to gain valuable insights into the specific interactions of 5-HT5AR ligand groups with the receptor.

Results: The obtained comprehensive set of 2160 compounds was divided into dozens of subsets, and a pharmacophore model was developed for each group. The results from the docking and molecular dynamics simulations have enabled the identification of crucial ligand-protein interactions that are essential for the compound's activity towards 5-HT5AR.

Conclusions: The findings from the molecular modeling study provide valuable insights that can guide medicinal chemists in the development of new 5-HT5AR ligands. Considering the pharmacological significance of these compounds, they have the potential to become impactful treatments for individuals and communities in the future. Understanding how different crystal/cryo-EM structures of 5-HT5AR affect molecular modeling experiments could have major implications for future computational studies on this receptor.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
参照 5-HT5AR 配体与靶蛋白的相互作用,揭示不同组 5-HT5AR 配体的独特特征。
背景:血清素 5-HT5A 受体吸引了更多研究人员的关注,这是因为其配体的治疗潜力正日益得到认可,而且这些研究结果还将带来更多的可能性。越来越多的证据表明,这些配体具有促进认知、促进社会和抗抑郁的特性,这为开发治疗方法提供了新的途径,可以解决与中枢神经系统功能失调有关的重要社会问题。我们的研究旨在揭示 5-HT5AR 配体对受体活性的分子决定因素:为了满足鉴定 5-HT5AR 活性分子决定因素的需要,我们精心收集了文献和专利数据,准备了一套全面的 5-HT5AR 配体。利用分子建模技术,如药效假说开发、对接和分子动力学模拟,我们得以深入了解 5-HT5AR 配体基团与受体的特定相互作用:结果:将获得的 2160 个化合物综合组划分为数十个子组,并为每个子组建立了药代模型。根据对接和分子动力学模拟的结果,确定了化合物对 5-HT5AR 的活性所必需的关键配体-蛋白质相互作用:分子建模研究的结果提供了宝贵的见解,可以指导药物化学家开发新的 5-HT5AR 配体。考虑到这些化合物的药理学意义,它们有可能在未来成为对个人和社区有影响的治疗方法。了解 5-HT5AR 的不同晶体/晶体-EM 结构如何影响分子建模实验,对未来有关该受体的计算研究具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacological Reports
Pharmacological Reports 医学-药学
CiteScore
8.40
自引率
0.00%
发文量
91
审稿时长
6 months
期刊介绍: Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures. Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology. Studies of plant extracts are not suitable for Pharmacological Reports.
期刊最新文献
Personalization of pharmacotherapy with sirolimus based on volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients-from LC-MS/MS method validation to clinical application. Correction: β-Carboline derivatives are potent against acute myeloid leukemia in vitro and in vivo. Long noncoding RNA MEG3: an active player in fibrosis. c-Myc inhibition and p21 modulation contribute to unsymmetrical bisacridines-induced apoptosis and senescence in pancreatic cancer cells. Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1